Trademark: 79324525
Word
ELATIVE
Status Date
Tuesday, September 27, 2022
Registration Number
6854744
Registration Date
Tuesday, September 27, 2022
Filing Date
Friday, June 25, 2021
Published for Opposition
Tuesday, July 12, 2022
5 Pharmaceutical preparations for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases, gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; organic biological preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; diagnostic preparations for medical use; diagnostic reagents for medical use
42 Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical products, in particular conducting clinical trials for others for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely providing information, results and data relating to scientific or medical research and development of pharmaceutical products, especially from an online searchable database; medical and scientific research, namely conducting clinical trials for others; pharmaceutical and biological development and research services for third parties; clinical research for others in the field of pharmaceuticals and medicines; evaluation of the efficacy of pharmaceutical products
The mark consists of the stylized word "ELATIVE" with the letters "ELATI" and the last letter "E" in blue and the letter "V" in orange.
The color(s) blue and orange is/are claimed as a feature of the mark.
Jan 25, 2023
Final Disposition Notice Sent To Ib
Jan 25, 2023
Final Disposition Processed
Dec 27, 2022
Final Disposition Notice Created, To Be Sent To Ib
Sep 27, 2022
Notice Of Registration Confirmation Emailed
Sep 27, 2022
Registered-Principal Register
Jul 19, 2022
Notification Processed By Ib
Jul 12, 2022
Official Gazette Publication Confirmation E-Mailed
Jul 12, 2022
Published For Opposition
Jun 29, 2022
Notification Of Possible Opposition Sent To Ib
Jun 29, 2022
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jun 22, 2022
Notification Of Notice Of Publication E-Mailed
Jun 9, 2022
Approved For Pub - Principal Register
Jun 8, 2022
Teas/Email Correspondence Entered
Jun 7, 2022
Correspondence Received In Law Office
Jun 7, 2022
Teas Response To Office Action Received
May 25, 2022
Refusal Processed By Ib
May 8, 2022
New Representative At Ib Received
May 4, 2022
Non-Final Action Mailed - Refusal Sent To Ib
May 4, 2022
Refusal Processed By Mpu
Mar 25, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Mar 24, 2022
Non-Final Action Written
Mar 17, 2022
Assigned To Examiner
Nov 12, 2021
Application Filing Receipt Mailed
Nov 8, 2021
New Application Office Supplied Data Entered
Nov 5, 2021
Limitation From Original Application Entered
Oct 28, 2021
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
